IL287486A - Heterologous administration of tau vaccines - Google Patents
Heterologous administration of tau vaccinesInfo
- Publication number
- IL287486A IL287486A IL287486A IL28748621A IL287486A IL 287486 A IL287486 A IL 287486A IL 287486 A IL287486 A IL 287486A IL 28748621 A IL28748621 A IL 28748621A IL 287486 A IL287486 A IL 287486A
- Authority
- IL
- Israel
- Prior art keywords
- tau
- vaccines
- heterologous
- administration
- heterologous administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837987P | 2019-04-24 | 2019-04-24 | |
| PCT/US2020/029477 WO2020219646A1 (en) | 2019-04-24 | 2020-04-23 | Heterologous administration of tau vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL287486A true IL287486A (en) | 2021-12-01 |
Family
ID=72921263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL287486A IL287486A (en) | 2019-04-24 | 2021-10-21 | Heterologous administration of tau vaccines |
Country Status (18)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| TW202333768A (zh) | 2017-10-25 | 2023-09-01 | 美商健生醫藥公司 | Tau胜肽之組成物及其用途 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| SG11202108312PA (en) | 2019-02-08 | 2021-08-30 | Ac Immune Sa | Method of safe administration of phosphorylated tau peptide vaccine |
| AU2021276616A1 (en) * | 2020-05-20 | 2023-01-05 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 and uses thereof |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| KR20240042508A (ko) * | 2021-08-12 | 2024-04-02 | 얀센 파마슈티칼즈, 인코포레이티드 | 지속적인 면역 반응을 유도하기 위한 인산화 타우 펩티드를 함유하는 리포솜 |
| EP4408864A4 (en) * | 2021-09-29 | 2025-09-03 | Janssen Pharmaceuticals Inc | METHOD FOR SAFE ADMINISTRATION OF A TAU PHOSPHOPEPTIDE CONJUGATE |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| AU690092B2 (en) | 1992-12-14 | 1998-04-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| WO1997034145A1 (fr) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
| WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| AU2001273361A1 (en) | 2000-07-11 | 2002-01-21 | Molecular Geriatrics Corporation | Reagents and methods for identification of binding agents |
| AU2003203079B9 (en) | 2002-02-04 | 2009-01-15 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| KR100994748B1 (ko) | 2002-04-19 | 2010-11-17 | 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 | 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물 |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| US20050261475A1 (en) | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
| US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| CA2633399C (en) | 2005-12-12 | 2016-01-26 | Ac Immune S.A. | Therapeutic vaccine |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
| KR20100115340A (ko) | 2007-10-19 | 2010-10-27 | 이무나스 파마 가부시키가이샤 | Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용 |
| MX2011009654A (es) | 2009-03-18 | 2011-10-12 | Ac Immune Sa | Metodo para uso terapeutico. |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| CN102596236B (zh) | 2009-07-30 | 2015-06-24 | 辉瑞疫苗有限责任公司 | 抗原性Tau肽及其用途 |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| EP2632434B1 (en) * | 2010-10-26 | 2025-08-20 | AC Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| AU2012272815B2 (en) * | 2011-06-22 | 2017-09-07 | The General Hospital Corporation | Treatment of proteinopathies |
| EP3275461A1 (en) * | 2011-09-19 | 2018-01-31 | Axon Neuroscience SE | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field |
| CN105939722A (zh) * | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽,抗Tau抗体,及其使用方法 |
| CA2952741A1 (en) | 2014-06-26 | 2015-12-30 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| EP3551220B1 (en) | 2016-12-07 | 2025-01-29 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| TW202333768A (zh) | 2017-10-25 | 2023-09-01 | 美商健生醫藥公司 | Tau胜肽之組成物及其用途 |
| CN111587123A (zh) * | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物 |
-
2020
- 2020-04-23 MX MX2021012994A patent/MX2021012994A/es unknown
- 2020-04-23 BR BR112021021213A patent/BR112021021213A2/pt not_active IP Right Cessation
- 2020-04-23 CN CN202080046201.9A patent/CN114173812B/zh active Active
- 2020-04-23 PH PH1/2021/552683A patent/PH12021552683A1/en unknown
- 2020-04-23 EA EA202192891A patent/EA202192891A1/ru unknown
- 2020-04-23 KR KR1020217038109A patent/KR20220005033A/ko not_active Ceased
- 2020-04-23 AU AU2020262899A patent/AU2020262899A1/en not_active Abandoned
- 2020-04-23 JO JOP/2021/0284A patent/JOP20210284A1/ar unknown
- 2020-04-23 TW TW109113654A patent/TW202110478A/zh unknown
- 2020-04-23 EP EP20796144.2A patent/EP3965817A4/en active Pending
- 2020-04-23 SG SG11202111770RA patent/SG11202111770RA/en unknown
- 2020-04-23 MA MA055902A patent/MA55902A/fr unknown
- 2020-04-23 CA CA3137884A patent/CA3137884A1/en active Pending
- 2020-04-23 JP JP2021563196A patent/JP7617852B2/ja active Active
- 2020-04-23 US US16/856,400 patent/US11591377B2/en active Active
- 2020-04-23 WO PCT/US2020/029477 patent/WO2020219646A1/en not_active Ceased
-
2021
- 2021-10-21 IL IL287486A patent/IL287486A/en unknown
- 2021-10-22 ZA ZA2021/08168A patent/ZA202108168B/en unknown
-
2023
- 2023-02-20 US US18/171,498 patent/US20230257433A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114173812A (zh) | 2022-03-11 |
| ZA202108168B (en) | 2022-09-28 |
| WO2020219646A1 (en) | 2020-10-29 |
| EP3965817A1 (en) | 2022-03-16 |
| JP2022529529A (ja) | 2022-06-22 |
| CA3137884A1 (en) | 2020-10-29 |
| US20230257433A1 (en) | 2023-08-17 |
| MX2021012994A (es) | 2022-03-04 |
| TW202110478A (zh) | 2021-03-16 |
| SG11202111770RA (en) | 2021-11-29 |
| CN114173812B (zh) | 2026-05-26 |
| KR20220005033A (ko) | 2022-01-12 |
| EP3965817A4 (en) | 2023-11-22 |
| JP7617852B2 (ja) | 2025-01-20 |
| PH12021552683A1 (en) | 2022-03-21 |
| JOP20210284A1 (ar) | 2023-01-30 |
| US11591377B2 (en) | 2023-02-28 |
| US20200339643A1 (en) | 2020-10-29 |
| MA55902A (fr) | 2022-03-16 |
| AU2020262899A1 (en) | 2021-11-18 |
| EA202192891A1 (ru) | 2022-02-04 |
| BR112021021213A2 (pt) | 2021-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202108168B (en) | Heterologous administration of tau vaccines | |
| IL282986B1 (en) | Colics-derivative carriers for oral administration of heterologous cargo | |
| IL275639A (en) | Formulation for RNA administration | |
| IL256173A (en) | Formulations for neoplasia compositions and methods for their preparation | |
| IL265856A (en) | Preparations for the administration of aflornithine | |
| ZA201908454B (en) | Solid preparation of cariprazine for oral administration | |
| IL281224A (en) | Peptide compounds | |
| IL285163A (en) | Method of safe administration of phosphorylated tau peptide vaccine | |
| IL291273A (en) | Intranasal administration of asketamine | |
| SG11202009147UA (en) | Vaccine compositions | |
| IL263126B (en) | Physiologically balanced injectable formulations of posantofitant | |
| SG11202105787QA (en) | Preparation including vaccine adjuvant | |
| GB201910794D0 (en) | Vaccine | |
| IL282245A (en) | Methods and compositions of polypeptide-based vaccines | |
| SG11202107203UA (en) | Mrna vaccine | |
| HK40068674A (en) | Heterologous administration of tau vaccines | |
| PL3615005T3 (pl) | Kompozycje i sposoby dostarczania szczepionki | |
| GB201811382D0 (en) | Vaccine | |
| GB201911636D0 (en) | Vaccine | |
| SG11202011004RA (en) | Hepatitis b vaccine transnasal administration system | |
| GB201807303D0 (en) | Glyconjugate vaccines | |
| HK40064748A (en) | Method of safe administration of phosphorylated tau peptide vaccine | |
| GB202013912D0 (en) | Single-dose live-attenuated YF17D-vectored vaccine against SARS-CoV-2 | |
| GB202010479D0 (en) | Single-dose live-attenuated YF17D-vectored vaccine against SARS-CoV-2 | |
| HK40052132A (en) | Peptide vaccines |